MICROWAVE PORATION THERAPY FOR PROSTATE CANCER

描述：(改编自调查人员摘要) 总的提案计划是开发临床可用的非侵入性 利用微波穿孔仪器增加对药物的摄取和保留 化疗药物通过靶向恶性细胞从而显着 增强这些制剂的抗癌活性。建议数 仪器由高峰值功率脉冲微波发生器组成，其 输出量由非侵入性涂抹器引导至肿瘤部位 在低平均功率水平下形成高电场的治疗 不会在暴露的组织中引起明显的温度升高。 在一项使用20只哥本哈根大鼠的初步初步研究中，它被证明 微波脉冲可以显著增加系统性摄取 植入循环荧光素葡聚糖(10,000道尔顿分子量) AT2例前列腺癌患者。对葡聚糖的摄取并不明显。 健康的细胞被脉冲化，表明有很大的治疗优势 可以通过微波脉冲获得。这项初步研究还表明 肿瘤的缓解可以通过联合微波脉冲和 全身给药的紫杉醇。在拟议的第一阶段计划期间，微波 仪器和治疗方案将使用哥本哈根大鼠进行优化 移植的AT2前列腺癌，以及器械和设备的设计 将考虑未来临床试验的治疗方案。 建议的商业应用： 癌症治疗：(1)较小剂量的化疗药物，从而减少全身 毒性。(2)单抗、放射性核和基因的治疗应用 靶向细胞膜的孔隙率增加将促进这一过程。 基因疗法不仅可以治疗癌症，还可以治疗从囊性纤维化到 艾滋病。

DESCRIPTION: (Adapted from investigator's abstract) The long-term objective of the overall proposal program is to develop clinically-usable non-invasive microwave poration instrumentation to increase the uptake and retention of chemotherapeutic agents by targeted malignant cells thereby significantly enhancing the anti-cancer activity of these agents. The proposed instrumentation consists of high-peak-power pulsed microwave generators whose output is directed by non-invasive applicators to the tumor site under treatment where high electric fields are developed at low average power levels that do not cause appreciable temperature increases in the exposed tissues. During a preliminary pilot study using 20 Copenhagen rats, it was demonstrated that microwave pulsing could sharply increase the uptake of systemically circulating fluorescin Dextran (10,000 daltons molecular weight) by implanted AT2 malignant prostate tumors. There was no significant uptake of Dextran by healthy cells that were pulsed indicating that a large therapeutic advantage can be obtained by microwave pulsing. This preliminary study also indicated that remission of tumors could be obtained by combining microwave pulsing and systemically administered Taxol. During the proposed Phase I program, microwave instrumentation and treatment protocols will be optimized using Copenhagen rats with implanted AT2 prostate tumors, and the design of instrumentation and treatment protocols for future clinical trials will be considered. PROPOSED COMMERCIAL APPLICATION: Cancer treatment: (1) Smaller doses of chemotherapeutic drugs, thus reducing systemic toxicity. (2) The therapeutic use of monoclonal antibodies, radioactive nuclei, and genes would be facilitated by the increased porosity of the targeted cell membranes. Gene therapy not only for cancer, but also for diseases ranging from cystic fibrosis to AIDS.